GLP-3 RETATRUTIDE (RETA)

$70.00

The Triple-Agonist “Super-Peptide”

Blacc Hammer Retatrutide represents the absolute frontier of metabolic research. As a first-of-its-class triple agonist, it targets three distinct hormonal pathways simultaneously: GLP-1, GIP, and Glucagon receptors. While previous generations targeted one or two of these receptors, Retatrutide’s unique “triple threat” design is being studied for its unprecedented impact on energy expenditure, fat oxidation, and glucose management.

Primary Research Applications

  • Triple-Pathway Synergy: Investigating the combined activation of GLP-1 (appetite), GIP (insulin/fat metabolism), and Glucagon (energy expenditure) receptors.

  • Resting Metabolic Rate (RMR): Studying the unique role of Glucagon receptor agonism in increasing fat burning and energy use, even at rest.

  • Hepatic Fat Reduction: Examining the peptide’s efficacy in reducing liver fat accumulation and its potential applications in studies of MASH (Metabolic Dysfunction-Associated Steatohepatitis).

  • Glycemic Control: Analyzing the dose-dependent effects on HbA1c levels and insulin sensitivity in metabolic models.

  • Appetite & Satiety Signaling: Exploring the central nervous system signals that suppress hunger and promote a long-lasting sense of fullness.

Why Retatrutide from Blacc Hammer Peptides?

Retatrutide is often highlighted for its unmatched potential within the research community. Blacc Hammer Peptides provides this groundbreaking molecule with complete batch traceability and third-party HPLC verification, ensuring researchers have reliable, high-purity material for long-term longitudinal studies without batch-to-batch variability.

Disclaimer: This product is intended strictly for laboratory research use only. It is not approved for human consumption, medical, or diagnostic use.